Fibrotic plaques in heart transplanted patients and their association with insulin resistance syndrome and Lp(a)

Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation

“…Based on information from Refs. [ [1] , [2] , [3] , [4] , [5] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [32] , [33] , [34] , [35] , [36] , [37] , [44] , [45] , [46] , [47] , [48] , [49] , [50] ]. The elements of the figure were created using SERVIER MEDICAL ART (CC BY 4.0).…”

“…Lp(a) ≥30 mg/dl (≥75 nmol/l) is found in 43 % of patients after HTx, and ≥50 mg/dl (≥125 nmol/l) in even 20 % of them [ 34 , 35 ]. It was shown that increased Lp(a) level in HTx patients may be associated with the risk of CAV (OR = 1.03; 95 % CI: 1.01–1.05) [ 36 ]. Another study found that elevated Lp(a) level was an independent risk factor for developing moderate to severe CAV (OR = 8.57; 95 % CI: 2.82–26.04) in the 1st year after HTx.…”